… use the path signature to provide features for identifying people whose diagnosis subsequently
converts to Alzheimer’s disease. … Is the Subject Area "Alzheimer's disease diagnosis and …

… assessment that does not use the clinical diagnosis as the point of reference. First, we
illustrate the key ideas when applying a single biomarker in this way and then proceed to build a …

… (B) We then extracted informed brain signatures enabling diagnosis. (C) … Alzheimer's disease
on the other hand. (D) We finally explored when the relevant features and brain signatures …

… In this way we were not biasing the experiment with ad hoc parameter selection and we
ensure the complete reproducibility of our claims. We are also aware that better results are …

… signatures for the prediction of group membership (AD or control) were constructed by way
of … Predictive performance of all models was assessed by way of (the comparison of) receiver …

Alzheimer’s disease (AD) manifests with progressive memory loss and spatial disorientation…
Because the EC harbors grid cells, a likely neural substrate of path integration (PI), we …

… In this way, we discovered associations between the identified drugs and identified putative
… signatures that indicate that they may influence important pathways influencing disease …

… For between-group mean comparisons, we used MANOVA and independent one-way
ANOVA or T test, whereas for within-group mean comparisons, we used independent one-way …

… If the current trend continues, the cases of Alzheimer's disease will increase … pathway
decreases the free glutamate level up to 83% in the pathway terminal zone of Alzheimer’s patients …

… GO and functional pathway terms were enriched within the DEG signatures using the … of
signaling pathways such as GPCR pathway, calcium signaling, neurotrophin signaling, opioid …